Evotec SE Unveils New Strategy and Provides 2025 Guidance Bolstered by Strong Q4 2024 Results
Rhea-AI Summary
Evotec SE (NASDAQ:EVO) has announced its FY 2024 results and unveiled a new strategic direction focused on drug discovery and biologics. The company reported a 2% revenue increase to €797.0 million, with Q4 2024 revenues up 10% to €221.2 million.
Key highlights include:
- Just - Evotec Biologics segment grew 71% year-over-year to €185.6 million
- Adjusted Group EBITDA reached €22.6 million
- Priority Reset program on track to deliver €40 million in annual savings
- Net debt leverage ratio improved to 1.9x
For 2025 guidance, Evotec expects:
- Revenue range of €840-880 million
- R&D expenditure of €40-50 million
- Adjusted Group EBITDA of €30-50 million
The company's 2028 outlook targets revenue CAGR of 8-12% (2024-2028) and adjusted EBITDA margin above 20%.
Positive
- Q4 2024 revenue grew 10% to €221.2 million
- Just - Evotec Biologics segment revenue surged 71% YoY
- Net debt leverage ratio improved to 1.9x
- New partnerships secured with Sandoz, BMS, Novo Nordisk, and Pfizer
- Priority Reset program to deliver €40 million annual savings
Negative
- Shared R&D revenues decreased 9% to €611.4 million
- Adjusted Group EBITDA declined to €22.6 million from €66.4 million in 2023
- One-off costs of €54.9 million from Priority Reset program
- Shared R&D revenues expected to remain flat in 2025
Insights
Evotec's strategic reset aims to improve profitability with promising growth in biologics, while overall financials show mixed performance requiring execution on cost initiatives.
Evotec's strategic repositioning marks a significant pivot toward sustainable profitability after a challenging 2024. The financial results reveal a company in transition, with modest 2% overall revenue growth to
The standout performer is the Just - Evotec Biologics segment, which delivered exceptional
The company's financial trajectory shows promise with Q4 delivering 10% revenue growth to
The company's dual cost-cutting initiatives—
Key partnerships with pharmaceutical giants like Bristol Myers Squibb, Pfizer, and Novo Nordisk provide valuable validation of Evotec's technology platform and create recurring revenue streams that support the 2028 targets of
Evotec's strategic refocus on drug discovery and biologics strengthens their market position, with impressive biologics growth offsetting softness in traditional services.
Evotec's strategic realignment represents a crucial evolution for the company, focusing on its scientific and technological strengths while addressing efficiency challenges. The decision to concentrate on two core pillars—Drug Discovery & Pre-clinical Development and Just - Evotec Biologics—aligns with industry trends toward specialized, high-value services powered by advanced technology.
The biologics business demonstrates exceptional commercial traction, growing
Evotec's portfolio rationalization, reducing assets by approximately
The expanded partnerships with major pharmaceutical companies validate Evotec's scientific approach and provide stable revenue streams. Particularly noteworthy are the extended Bristol Myers Squibb collaboration in neuroscience and protein degradation, the Novo Nordisk cell therapy initiative, and the Pfizer partnership focusing on metabolic and infectious diseases—all representing high-value therapeutic areas.
While the
Evotec sharpens focus on pioneering drug discovery and charts clear path toward sustainable profitable growth
Strategy builds on technology and science leadership, focusing on high-growth, high-value segments, simplifying the business model and fostering operational excellence
Strong Q4 2024 revenue and EBITDA results in spite of challenging market conditions. Full year guidance met, with liquidity significantly improved
Priority Reset on track to deliver annualised recurring gross savings of € 40 m
2025 guidance: group revenues to grow 5 - 10 % (€ 840 - 880 m); 2028 outlook foresees revenue CAGR2024-2028 between 8 -
12% and generation of EBITDA margin above 20 %
HAMBURG, GERMANY / ACCESS Newswire / April 17, 2025 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN:DE0005664809; NASDAQ:EVO) today announced its financial results for FY 2024, provided guidance for FY 2025 and outlook for 2028 reflecting the path to sustainable profitable growth, following the completion of its strategic review process.
Dr Christian Wojczewski, Chief Executive Officer of Evotec, said:
"Evotec's ambitious new direction paves the way for sustainable profitable long-term growth. We are refocusing Evotec on its core strengths: technology and science leadership, where we deliver maximum impact for customers and patients. By combining cutting-edge technology platforms, disruptive science, and AI-driven innovation, we are accelerating the journey from concept to cure with our partners. We delivered on 2024 financial guidance, and I am excited about the opportunities that lie ahead of us. Together with our talented teams, we are writing the next chapter of Evotec's success story as a drug discovery pioneer."
Evotec unveils new strategy to refocus on core strengths and define clear roadmap to sustainable profitable growth
Technology and science leadership - refocusing on our strong, unique heritage
Two pillars: Drug Discovery & Pre-clinical Development (Shared R&D) and Just - Evotec Biologics
Drug Discovery & Pre-clinical Development will leverage automation, industrialisation, next generation platforms and AI to accelerate our customers journey and to increase their success rates
Business model simplified: focus on high-value services and therapeutic areas, asset portfolio streamlined by ~30 %, R&D supporting next-generation technology development. Exiting equity participations
Just - Evotec Biologics growth underpinned by existing partnerships and further strengthened by leveraging its capabilities as a scalable technology and service provider, anticipating pivot to an asset lighter model
Beating market growth via our scientific and operational expertise, focus, and differentiated technology
Commitment to operational excellence for a step-change in performance. Driving operational leverage through our backbone with higher focus on automation. Anchored cost-out initiatives via refined footprint, optimised COGS and SG&A delivering > € 50 m gross savings by 2028 on top of Priority Reset (€ 40 m)
2024 revenue and EBITDA within guidance. Priority Reset on track. Q4: Second highest quarterly revenues ever amid challenging market environment
Group revenues increased by 2 % to € 797.0 m (2023: € 781.4 m); Q4 2024 revenues increased by 10 % to € 221.2 m from € 201.3 m in Q4 2023
Evotec's Just - Evotec Biologics segment saw impressive growth, with revenues rising by 71 % year-over-year, contributing € 185.6 m (2023: € 108.4 m) to the overall topline
Total Shared R&D revenues decreased by 9 % to € 611.4 m (2023: € 673.0 m); Demand still affected by temporary Pharma restructuring and selective funding for Biotech
Adjusted Group EBITDA totalled € 22.6 m (2023: € 66.4 m) driven by a mismatch between revenues and cost base in the Shared R&D segment
Priority Reset on track to secure an annualised adjusted EBITDA improvement of over € 40 m. One-off costs recognised at € 54.9 m, vs. initial provision of € 68.5 m
Net debt leverage ratio significantly improved to 1.9x net debt / EBITDA
Strengthened partnerships in 2024 paving the way for 2025 growth in soft market environment
Group revenue growth expected to accelerate vs. 2024, driven by Just - Evotec Biologics, while Shared R&D revenues expected to remain around 2024 levels
Tariffs & US government funding development are expected to have a limited impact on Evotec's business
Expansion of technology partnership with Sandoz and new customers for long-term development and commercial manufacturing in Biologics
Progress and extension of multi-year collaboration with Bristol Myers Squibb ("BMS") in neuroscience and targeted protein degradation
New technology development partnership with Novo Nordisk to support next-generation cell therapies
New multi-year master research collaboration with Pfizer, initially focusing on early discovery research for metabolic and infectious diseases
Guidance for full-year 2025
Group revenues expected in the range of € 840 - 880 m (2024: € 797.0 m)
R&D expenditures are expected in a range of € 40 - 50 m (2024: € 50.8 m)
Adjusted Group EBITDA is expected to reach € 30 - 50 m (2024: € 22.6 m)
Outlook 2028
Group revenues CAGR 2024-2028 targeted to be in a range of 8 - 12 %
Adj. EBITDA margin 2028 expected to be above 20 %
CAGR: Compound annual growth rate
More detailed information and financial tables are available in the annual report published on the Evotec website under the following link: https://www.evotec.com/en/investor-relations/financial-publications
Webcast/Conference Call
The Company plans to hold a conference call to discuss the results as well as provide an update on its performance. The conference call will be held in English.
Webcast details
Date: Thursday, 17 April 2025
Time: 2.00 pm CEST (01.00 pm BST, 08.00 am EDT)
To join the audio webcast and to access the presentation slides, please register via this link.
The on-demand version of the webcast will be available on our website: www.evotec.com/en/investor-relations/financial-publications.
Conference call details
To join via phone, please pre-register via this link.
You will then receive a confirmation email with dedicated dial-in details such as telephone number, access code and PIN to access the call.
A simultaneous slide presentation for participants dialling in via phone is available under this link.
About Evotec SE
Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company's multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec provides high value pipeline co-creating partnerships and solutions to all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 100 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 4,800 highly qualified people. The Company's sites in Europe and the USA offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on X/Twitter @Evotec and LinkedIn.
Forward-looking-statements
This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
For further information, please contact:
Investor Relations
Volker Braun
EVP Head of Global Investor Relations & ESG
volker.braun@evotec.com
SOURCE: Evotec SE
View the original press release on ACCESS Newswire
FAQ
What are Evotec's (EVO) revenue projections for 2025?
How much did Evotec's (EVO) biologics segment grow in 2024?
What cost savings will Evotec's Priority Reset program deliver?
What is Evotec's (EVO) EBITDA margin target for 2028?
How much did Evotec's (EVO) Q4 2024 revenue grow?
